Fibronectin in the extracellular matrix of tissues acts as a substrate for cell adhesion and migration during development. Heterogeneity in the structure of fibronectin is largely due to the alternative splicing of at least three exons (IIIB, IIIA, and V) during processing of a single primary transcript. Fibronectin mRNA alternative splicing patterns change from B+A+V+ to B+A-V+ during chondrogenesis. In this report, immunohistochemical analysis demonstrates that while fibronectin protein containing the region encoded by exon IIIB is present throughout the limb at all stages of development, fibronectin protein containing the region encoded by exon IIIA disappears from cartilaginous regions just after condensation in vivo and in high-density mesenchymal micromass cultures in vitro. Treatment of mesenchymal micromass cultures prior to condensation with an antibody specific for the region encoded by exon IIIA disrupts the formation of cellular condensations and inhibits subsequent chondrogenesis in a dose- and time-dependent manner. Furthermore, microinjection of the exon IIIA antibody into embryonic chick limb primordia in vivo results in malformations characterized by smaller limbs and loss of limb skeletal elements. These results strongly suggest that the presence of the region encoded by exon IIIA in mesenchymal fibronectin is necessary for the condensation event that occurs during chondrogenesis.
The embryonic skull bone, the calvarium, develops via intramembranous ossification, whereby mesenchymal cells differentiate directly into osteoblasts. However, under certain conditions, such as systemic calcium deficiency, regions of cartilage-like tissue are observed in the chick embryonic calvarium, suggesting the presence of pre-cartilage cells. We have recently identified and isolated a chondrogenic cell subpopulation from chick embryonic calvarium by Percoll gradient centrifugation. Using peanut agglutinin (PNA), which has been shown to bind specifically to chondroprogenitor cells in various developing skeletal elements, we have further examined the chondrogenic characteristics of calvarial cells. Histochemical staining of calvaria sections showed the presence of PNA-binding cells in subcambial regions of the calvarium as a function of embryonic development and calcium status. PNA-binding activity was also used as the basis for affinity chromatography fractionation of calvarial cells isolated from normal and calcium-deficient, shell-less chick embryos. A higher percentage of calvarial cells from the normal embryo bound PNA than those from shell-less embryos. Interestingly, more PNA-binding cells were found in the dense, chondrogenic fractions obtained by prior Percoll gradient fractionation of calvarial cells. The chondrogenic potential of the PNA affinity fractionated cells was assessed in culture based on alcian blue staining, and expression of collagen type II and aggrecan core protein. PNA-binding cells isolated from total calvarial cells and from the dense Percoll fractions exhibited a prominent chondrocyte-like phenotype, and were organized in alcian blue-stained nodules, which immunostained positively for collagen type II and aggrecan. Expression of collagen type II was also detected at the mRNA level by means of coupled reverse transcription/polymerase chain reaction. On the other hand, non-PNA-binding cells, isolated from total calvarial cells and from the lighter Percoll fractions, were primarily fibroblastic in appearance and did not express cartilage-associated characteristics. The presence of distinct PNA-binding cells with chondrogenic potential strongly suggests that these cells may be functionally important in morphogenesis of the embryonic calvarium.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.